High Risk of Infection During Triple Therapy with First-Generation Protease Inhibitors: A Nationwide Cohort Study
High Risk of Infection During Triple Therapy with First-Generation Protease Inhibitors: A Nationwide Cohort Study
复制标题
DOI：
10.15403/jgld.2014.1121.252.th3
复制
发表时间：
2016-06-01
影响因子：
2.1
通讯作者：
Drenth, Joost P. H.
中科院分区：
文献类型：
--
作者：
Berden, Floor A. C.;van Zwietering, Inke M. J. M.;Drenth, Joost P. H.
背景与目的：聚乙二醇干扰素（PegIFN）仍然是经济拮据地区治疗慢性丙型肝炎（CHC）的主要药物。然而，PegIFN可能导致中性粒细胞减少症，添加蛋白酶抑制剂可能增加中性粒细胞减少症的可能性。本研究的目的是评估第一代蛋白酶抑制剂为基础的治疗过程中临床相关感染的发生及其危险因素，以及治疗诱导的neutrophilia.Methods的关系：这个多中心（n=45）回顾性队列研究包括CHC患者在荷兰治疗。根据中性粒细胞绝对计数，中性粒细胞减少症的分类定义为：重度（
Background & Aims: Peginterferon (PegIFN) remains the backbone of therapy for chronic hepatitis C (CHC) in economically constrained regions. However, PegIFN may cause neutropenia and addition of a protease inhibitor can increase the likelihood of neutropenia. The aims of this study were to assess the occurrence of clinically relevant infections during first -generation protease inhibitor based therapy and its risk factors as well as the relation to treatment-induced neutropenia.Methods: This multicenter (n=45) retrospective cohort study included CHC patients treated in the Netherlands. Based on absolute neutrophil count, categories of neutropenia were defined as: severe (